Cite
HARVARD Citation
Sanborn, R. et al. (2021). CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. Journal for immunotherapy of cancer. 9 (7), p. . [Online].